Dimitris Agrafiotis, PhD, FRSC, is Chief Information Officer of the Novartis Institutes for Biomedical Research, where he is responsible for leading Novartis’ global technology and informatics organization for its research and early development division. Dr. Agrafiotis received his PhD in Theoretical Chemistry from Imperial College London in 1988, and held postdoctoral fellowships at the University of California, Berkeley and Harvard, where he worked with Nobel laureate EJ Corey. In 1991, he joined Parke-Davis as a Senior Scientist in the computational drug design group, and in 1994 he moved to 3-Dimensional Pharmaceuticals as a founding member of its scientific staff, responsible for building the company’s informatics and computational drug design capabilities. Following a successful IPO and the acquisition of the company by Johnson & Johnson in 2003, he was appointed Senior Research Fellow and Team Leader of Molecular Design and Informatics, a position he held until 2006 when he was appointed global head of Informatics and Research and Early Development IT. In 2013, he moved to Covance as Chief Data Officer and Head of Technology Products where he developed Xcellerate, an award-winning clinical platform and the first software-as-a-service offering in the company’s history. His work is documented in 100 peer-reviewed publications and book chapters and 18 issued US patents. In 2012 he was elected Fellow of the Royal Society of Chemistry for his contributions to chemical and pharmaceutical research, and in 2016 he was named in Computerworld’s Premier 100 Technology Leaders for his technology leadership and innovative approaches to business challenges.


DAY 1 / ‏‏‎ ‎

09:00 AM - 09:40 AM
Plenary View Session

Executive Viewpoints Debate: What Will it Take to Make the Use of AI/ML Tools Scalable?

  • How do you translate AI/ML technology into patient impact
    • Better treatments
    • Higher quality outcomes
    • Less adverse effect
  • Streamlining processes enterprise-wide
Dimitris K. Agrafiotis, PhD, Chief Information Officer, Novartis Institutes for BioMedical Research (NIBR)
Niven R. Narain, Ph.D, Co-Founder, President & CEO, BERG
Andrew Radin, CEO & Co-Founder, twoXAR Pharmaceuticals

Never miss an announcement

/* */